

Community Health Network Oncology Research - Enrolling Clinical Trials

3/3/2026

Multiple Disease Sites		NCT #	Study Drug MOA	Indication/Population	Biomarker Target	Sites Open
AbbVie M21-410	A Global First-in-Human Study in NSCLC, HNSCC, and Solid Tumors with Azirkitug as a Single Agent and in Combination(s) with Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan	NCT05005403	ABBV-514 is a T-regs cell depleter	Colorectal, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma	NA	Indy
Artios ART0380C001	A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors	NCT04657068	ART0380	Advanced or metastatic solid tumors w/ATM alterations	ATM	North
Arvinas ARV-806-101	A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors	NCT07023731	KRAS G12D degrader	Advanced Solid Tumors	KRAS G12D	Indy
Boehringer Ingelheim 1479-0009	Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumour	NCT06581432	BI 1810631	HER2-mutated or overexpressed/amplified solid tumours	HER2	North & East (South Pending)
DualityBio DB-1311-201	Phase II clinical study for DB-1311 in Combination with BNT327 or DB1305 for patients with Advanced Solid Tumors	NCT05914116	B7-H3 IgG1 ADC	Advanced/Metastatic Solid Tumors (Hepatocellular Carcinoma, Cervical Cancer, Melanoma, Head & Neck Squamous Cell Carcinomas, NSCLC)	B7H3, PD-L1, TROP2 and others	Indy
Endeavor ENV-ONC-501	A First-in-Human, Open-label, Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ENV-501 in Patients with Advanced-Stage, Relapsed/Refractory HER3-Expressing Solid Tumors	NCT06956690	ENV-501	Advanced-Stage, Relapsed/Refractory HER3-Expressing Solid Tumors	HER3	North Only
GV20 Therapeutics GV20-0251-100	An Open-Label Study of GV20-0251 in Patients with Advanced and/or Refractory Solid Tumor Malignancies	NCT05669430	IGSF8 antibody	Advanced and/or Refractory Solid Tumor Malignancies (Currently enrolling in Melanoma only)	IGSF8 and others	North and South

InSilico Medicine ISM3412-101	A Phase 1, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM3412 in Participants with Locally Advanced/Metastatic Solid Tumors	NCT06414460	ISM3412	Locally Advanced/Metastatic Solid Tumors	Various	Indy
KaliVir STEALTH-001	A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors	NCT06444815	VET3-TGI	Advanced Solid Tumors IV Cohort Only	Various	Indy
Lilly J5J-OX-JZZA	Phase 1a/1b Study of LY3962673 in Patients with KRAS G12D-Mutant Solid Tumor	NCT06586515	LY3962673	KRAS G12D-Mutant Solid Tumors	KRAS G12D	Indy
Lilly/LOXO LOXO-RAS-20001	A Phase 1/2 Study of LY3537982 in Patients with KRAS C12C-Mutant Advanced Solid Tumors	NCT04956640	KRAS G12C Inhibitor	Non Small Cell Lung Cancer, Pancreatic	KRAS G12C	Indy
MDA TAPUR	The Targeted Agent and Profiling Utilization Registry (TAPUR) Study	NCT02693535	Various	Various	Various	Indy
Relay Therapeutics RLY-2608-101	Relay Therapeutics RLY-2608-101, A First-in-Human Study of Mutant-selective PI3K α Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer	NCT05216432	RLY-2608	Unresectable or metastatic solid tumors	PIK3CA	North and South
Seagen SGNB6A-001	A Phase 1 Study of SGN-B6A in Advanced Solid Tumors	NCT04389632	ADC targeting integrin beta-6	Dose expansion Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma	Integrin beta-6	Indy
Servier CL1-95035-001	A Phase 1, open-label, multicenter clinical trial of S095035 (MAT2A inhibitor) in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP	NCT06188702	MAT2A inhibitor	Advanced or metastatic solid tumors	MTAP	North (South & East Pending)
Tempus TP-CA-005	Polaris - Umbrella Study for Analysis of Data Related to Patients with Cancer	NCT06018753	N/A - data collection only	Subjects diagnosed with cancer	N/A	Indy
Volastra VLS-1488-2201	A phase I/II study of VLS-1488 (an oral KIF18A inhibitor) in subjects with advanced cancer	NCT05902988	Oral KIF18A Inhibitor	Squamous Non Small Cell Lung Cancer, Head and Neck Squamous Cell Cancer, High Grade Serous Ovarian, Fallopian tube or primary peritoneal	KIF18A	North and South

Breast		NCT #	Study Drug MOA	Indication/Population	Biomarker Target	Sites Open
CCTG MA.39	A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer	NCT03488693	RT	Low-risk breast cancer (Oncotype DX ≤25) or T3N0 disease	ER+	Indy
Relay Therapeutics RLY-2608-101	A First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer	NCT05216432	PI3Kα inhibitor	HR+, HER2- locally advanced or metastatic breast cancer	PIK3CA HR+, HER2-	North and South
Relay Therapeutics RLY-2608-102	Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor	NCT06982521	PI3Kα inhibitor	HR+/HER2- metastatic or locally advanced breast cancer	PIK3CA HR+, HER2-	Indy

Gastrointestinal		NCT #	Study Drug MOA	Indication/Population	Biomarker Target	Sites Open
AbbVie M21-410	A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors with ABBV-514 as a Single Agent and in Combination with Pembrolizumab or Budigalimab	NCT05005403	ABBV-514 is a T-regs cell depleter	Colorectal Cancer	NA	Indy
AbbVie M24-064	An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing ABBV-400 Monotherapy to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with c-Met Over-Expressed Refractory Metastatic Colorectal Cancer	NCT06614192	ABBV-400 / ADC	c-Met Over-Expressed Refractory Metastatic Colorectal Cancer	c-Met	Indy
Artios ART0380C001	A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors	NCT04657068	ART0380	Advanced or metastatic solid tumors w/ATM alterations Pancreatic	ATM	North
DualityBio DB-1311-201	Phase II clinical study for DB-1311 in Combination with BNT327 or DB1305 for patients with Advanced Solid Tumors	NCT05914116	B7-H3 IgG1 ADC	Advanced/Metastatic Solid Tumors - Hepatocellular Carcinoma	B7H3, PD-L1, TROP2 and others	Indy
Janssen 89402638GIC1001	A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer	NCT06663319	ADC	Unresectable Metastatic Colorectal Cancer	GUCY2C	North Only

Lilly J5J-OX-JZZA	Phase 1a/1b Study of LY3962673 in Patients with KRAS G12D-Mutant Solid Tumor	NCT06586515	LY3962673	KRAS G12D-Mutant Solid Tumors Colorectal Cancer, Pancreatic Ductal Adenocarcinoma	KRAS G12D	Indy
Lilly/LOXO LOXO-RAS-20001	A Phase 1/2 Study of LY3537982 in Patients with KRAS C12C-Mutant Advanced Solid Tumors	NCT04956640	KRAS G12C Inhibitor	Pancreatic, Colorectal Cancer	KRAS G12C	Indy
MDA TAPUR	The Targeted Agent and Profiling Utilization Registry (TAPUR) Study	NCT02693535	Various	Colorectal Cancer	Various	Indy
Revolution Medicines RMC-6236-304	RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib versus Observation Following Curative Intent Therapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)	NCT07252232	Daraxonrasib RAS(ON) inhibitor	Resected PDAC	B7H3, PD-L1, TROP2 and others	Indy

Genitourinary		NCT #	Study Drug MOA	Indication/Population	Biomarker Target	Sites Open
Pathos P300-02-001	A Phase 1b/2a, Multicenter, Open-Label Study of Pocembrodib as Monotherapy and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)	pending	CBP/p300 inhibitor	mCRPC	PSA	North & South (East Pending)

Gyn		NCT #	Study Drug MOA	Indication/Population	Biomarker Target	Sites Open
Daiichi DS6000-109 GOG-3096	A Phase 2/3 randomized study of a Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancers	NCT06161025	CDH6-directed Antibody-drug Conjugate	Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (at least 1, but no more than 3, prior systemic lines)	CDH6	Indy
DualityBio DB-1311-201	Phase II clinical study for DB-1311 in Combination with BNT327 or DB1305 for patients with Advanced Solid Tumors	NCT05914116	B7-H3 IgG1 ADC	Advanced/Metastatic Solid Tumors - Cervical Cancer	B7H3, PD-L1, TROP2 and others	Indy
Kelun SKB264-II-06	A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination with Pembrolizumab in Subjects with Selected Solid Tumors	NCT05642780	TROP2 monoclonal antibody (mAb) of immunoglobulin (Ig)G1 class & toxin molecule KL610023	2L or 3L recurrent or metastatic cervical cancer	TROP2	North
Volastra VLS-1488-2201	A phase I/II study of VLS-1488 (an oral KIF18A inhibitor) in subjects with advanced cancer	NCT05902988	Oral KIF18A Inhibitor	High grade serous ovarian, fallopian tube or primary peritoneal cancer	KIF18A	North and South

Zentalis ZN-c3-005 GOG-3066	A Phase 2 Open-Label, Multicenter, Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer (DENALI)	NCT05128825	WEE-1 Inhibitor	High grade serous ovarian	CCNE1 amplification, cyclin E1 protein expression	Indy
--------------------------------	--	-------------	-----------------	---------------------------	---	------

Head and Neck		NCT #	Study Drug MOA	Indication/Population	Biomarker Target	Sites Open
AbbVie M21-410	A Global First-in-Human Study in NSCLC, HNSCC, and Solid Tumors with Azirkitug as a Single Agent and in Combination(s) with Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan	NCT05005403	ABBV-514 is a T-regs cell depleter	Head and Neck Squamous Cell Carcinoma	NA	Indy
DualityBio DB-1311-201	Phase II clinical study for DB-1311 in Combination with BNT327 or DB1305 for patients with Advanced Solid Tumors	NCT05914116	B7-H3 IgG1 ADC	Advanced/Metastatic Solid Tumors - Head & Neck Squamous Cell Carcinomas	B7H3, PD-L1, TROP2 and others	Indy
Seagen SGNB6A-001	A Phase 1 Study of SGN-B6A in Advanced Solid Tumors	NCT04389632	ADC targeting integrin beta-6	Dose expansion: Head and Neck Squamous Cell Carcinoma	Integrin beta-6	Indy
Volastra VLS-1488-2201	A phase I/II study of VLS-1488 (an oral KIF18A inhibitor) in subjects with advanced cancer	NCT05902988	Oral KIF18A Inhibitor	Head and Neck Squamous Cell Cancer	KIF18A	North and South

Hematology		NCT #	Study Drug MOA	Indication/Population	Biomarker Target	Sites Open
MDA TAPUR	The Targeted Agent and Profiling Utilization Registry (TAPUR) Study	NCT02693535	Various	Multiple Myeloma, B cell Non-Hodgkin Lymphoma	Various	Indy
Pfizer C1071032	MAGNETISMM-32: A Phase 3, Open-Label Study of Elranatamab Monotherapy Versus Elotuzumab, Pomalidomide, Dexamethasone (EPd) or Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed/Refractory Multiple Myeloma Who Received Prior Anti-CD38 Directed Therapy	NCT06152575	BsABS against BCMA and CD3	Relapsed/Refractory Multiple Myeloma	Various	North for C1D1 & C1D4 (if C1D1 is not tolerated well); open @ South for all other cycles

Lung		NCT #	Study Drug MOA	Indication/Population	Biomarker Target	Sites Open
AbbVie M21-410	A Global First-in-Human Study in NSCLC, HNSCC, and Solid Tumors with Azirkitug as a Single Agent and in Combination(s) with Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan	NCT05005403	ABBV-514 is a T-regs cell depleter	Non Small Cell Lung Cancer	NA	Indy

AbbVie M24-536	An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination with Budigalimab in Advanced or Metastatic Non-Squamous NSCLC with No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations	NCT06772623	ABBV-400	Advanced or Metastatic Non-Squamous Non Small Cell Lung Cancer	Various	Indy
Ankyra ANK-101-004	A Phase 2, Two-Part Study of Tolododekin Alfa (ANK-101) in Combination with PD1 in Participants with Advanced Non-Small Cell Lung Cancer	NCT07027514	ANK-101	Non Small Cell Lung Cancer	Various	Indy
Boehringer Ingelheim 1479-0009	Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumour	NCT06581432	BI 1810631	Non Small Cell Lung Cancer	HER2	North & East (South Pending)
DualityBio DB-1311-201	Phase II clinical study for DB-1311 in Combination with BNT327 or DB1305 for patients with Advanced Solid Tumors	NCT05914116	B7-H3 IgG1 ADC	Advanced/Metastatic Solid Tumors - Non Small Cell Lung Cancer	B7H3, PD-L1, TROP2 and others	Indy
Lilly J3M-MC-JZQB	SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression $\geq 50\%$ or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression	NCT06119581	LY3537982 in combination with Pembrolizumab Pemetrexed and Platinum	KRAS G12C-Mutant, Locally Advanced or Metastatic Non Small Cell Lung Cancer	KRAS G12C-Mutant	North and South
Lilly J5J-OX-JZZA	Phase 1a/1b Study of LY3962673 in Patients with KRAS G12D-Mutant Solid Tumor	NCT06586515	LY3962673	KRAS G12D-Mutant Solid Tumors Non Small Cell Lung Cancer	KRAS G12D	Indy
Lilly/LOXO LOXO-RAS-20001	A Phase 1/2 Study of LY3537982 in Patients with KRAS C12C-Mutant Advanced Solid Tumors	NCT04956640	KRAS G12C Inhibitor	Non Small Cell Lung Cancer	KRAS G12C	Indy
Seagen SGNB6A-001	A Phase 1 Study of SGN-B6A in Advanced Solid Tumors	NCT04389632	ADC targeting integrin beta-6	Dose expansion: Non Small Cell Lung Cancer	Integrin beta-6	Indy
Volastra VLS-1488-2201	A phase I/II study of VLS-1488 (an oral KIF18A inhibitor) in subjects with advanced cancer	NCT05902988	Oral KIF18A Inhibitor	Dose expansion: sq-Non Small Cell Lung Cancer	KIF18A	North and South

Melanoma		NCT #	Study Drug MOA	Indication/Population	Biomarker Target	Sites Open
DualityBio DB-1311-201	Phase II clinical study for DB-1311 in Combination with BNT327 or DB1305 for patients with Advanced Solid Tumors	NCT05914116	B7-H3 IgG1 ADC	Advanced/Metastatic Solid Tumors - Melanoma	B7H3, PD-L1, TROP2 and others	Indy
GV20 Therapeutics GV20-0251-100	GV20-0251-100, An Open-Label Study of GV20-0251 in Patients with Advanced and/or Refractory Solid Tumor Malignancies	NCT05669430	IGSF8 antibody	Cutaneous melanoma	IGSF8 and others	North and South